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ABSTRACT 
Even though severe sepsis and septic shock therapy has improved in recent years, 
mortality remains high (22-50%). Disturbances in splanchnic organ homeostasis and 
increases in gut permeability have long been presumed to contribute to systemic 
inflammation and multiple organ dysfunction syndrome in critical illness and septic 
shock. In recent years, microcirculatory dysfunction has been highlighted as an 
important player in the development of sepsis-induced organ failure. This thesis 
investigated splanchnic microcirculatory changes during endotoxaemia, and the 
microcirculatory effects of ethyl pyruvate, endothelin (ET) receptor antagonists, and a 
norepinephrine-induced increase in perfusion pressure. Laser Doppler flowmetry 
(papers I-IV) and sidestream dark field microscopy (paper IV) were used to evaluate 
the microcirculation.  
In papers I-III a 5-hour model of porcine endotoxaemia was used. In this model, the 
systemic haemodynamic response to endotoxin was hypodynamic, with decreasing 
cardiac index (CI), hypotension, and systemic acidosis. Splanchnic regional blood flow 
and microcirculatory perfusion deteriorated, and ileal mucosal acidosis measured with 
air tonometry developed in parallel. 
Although intervention with the resuscitation fluid Ringer’s ethyl pyruvate solution 
(REPS) temporarily improved systemic haemodynamics, no major differences in 
haemodynamic parameters or splanchnic perfusion were found compared to standard 
therapy with Ringer’s acetate (RA).    
The mixed ETA/ETB receptor antagonist tezosentan did not increase superior 
mesenteric artery flow (SMAF), but microcirculatory perfusion in the ileal mucosa and 
ileal mucosal acidosis was still improved. Tezosentan also increased portal vein flow 
compared to controls, but no significant improvement of hepatic microcirculatory 
perfusion could be demonstrated. Selective endothelinA receptor antagonism with 
TBC3711 failed to improve splanchnic regional blood flow, splanchnic 
microcirculatory perfusion or ileal mucosal acidosis.  
A 25-hour model of endotoxaemic shock in sheep, mimicking the hyperdynamic 
circulation seen in septic patients, was used in paper IV. After 24 hours of 
endotoxaemia, CI was increased and systemic hypotension had developed. Although 
SMAF also increased, microcirculation in the ileal mucosa and muscularis was 
disturbed, ileal mitochondrial complex I activity decreased, and ileal mucosal acidosis 
developed. Increasing perfusion pressure with norepinephrine after 24 hours of 
endotoxaemia did not significantly alter SMAF, ileal microcirculation, ileal 
mitochondrial enzyme activity or ileal mucosal acidosis.  
In conclusion, gut microcirculatory alterations have a weak correlation to systemic and 
regional indices of flow and pressure in endotoxaemia, strengthening the hypothesis 
that monitoring and therapies directed towards the microcirculation could be of value in 
sepsis. The ET system is involved in the development of gut microcirculatory 
dysfunction in endotoxaemia, and mixed ET receptor antagonism is necessary to 
counteract the effects of ET in this context. Resuscitation with REPS does not appear to 
have initial positive haemodynamic or microcirculatory effects compared to RA. 
Key words: Microcirculation, endotoxin, sepsis, pig, sheep, endothelin, ethyl pyruvate, 
gut, liver, splanchnic circulation, shock, tonometry, norepinephrine     
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INTRODUCTION 
BACKGROUND 
The treatment of severe sepsis is a challenge to the intensive care unit (ICU) physician, 
and severe sepsis and septic shock remain leading causes of death in non-coronary ICU 
patients. Even though therapy has improved with the introduction of protocols mainly 
guided by systemic haemodynamic variables, mortality remains high (22-50%), and the 
pathophysiology of septic shock remains to be fully elucidated1. In recent years, 
microcirculatory dysfunction has been suggested to play an important role in the 
development of sepsis-induced organ failure2. In septic patients with comparable 
systemic haemodynamics, persistent microcirculatory alterations have been correlated 
to patient outcome3, and therapies targeting the microcirculation have been proposed as 
a new therapeutic strategy in sepsis. Presumably, a deeper understanding of the factors 
contributing to this microcirculatory failure could contribute to the development of 
better therapies for patients with severe sepsis. 
Perfusion derangements in the splanchnic organs may compromise the barrier function 
of the intestinal mucosa, facilitating the translocation of bacteria and toxins to the blood 
and lymph, with subsequent activation of systemic inflammation. Moreover, the gut 
and the liver have important immunologic functions, and therapies aimed at restoring 
microcirculatory blood flow and preventing splanchnic organ dysfunction could 
potentially be of major importance in the treatment of sepsis. This thesis investigated 
splanchnic microcirculatory changes during endotoxaemia, and the microcirculatory 
effects of ethyl pyruvate, endothelin receptor antagonists, and a norepinephrine-induced 
increase in perfusion pressure.   
THE CIRCULATORY SYSTEM 
The main functions of the circulatory system are the maintenance of tissue homeostasis 
and the convective transport of nutrients, cells, gases, waste products and hormones. 
The heart serves as the central pump circulating blood through a continuous system of 
blood vessels. Cardiac output (CO) is the volume of blood being pumped by the heart 
per minute, a function of heart rate (HR) and stroke volume. The main determinants of 
stroke volume are preload, afterload and cardiac contractility. Cardiac output is 
continuously regulated to meet the demands of the tissues.  
The driving pressure for blood in the systemic circulation is the difference between 
mean arterial pressure (MAP) and central venous pressure (CVP). Correspondingly, the 
perfusion pressure for a specific organ is calculated as the difference between the mean 
arterial pressure and the venous pressure in that specific tissue. MAP is primarily 
determined by cardiac output and systemic vascular resistance (SVR). The relationship 
between CO, MAP, CVP and SVR is given by the equation: CO = (MAP-CVP)/SVR. 
A. Andersson 
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The microcirculation 
The microcirculation is usually defined as blood vessels with a diameter <100 µm, and 
includes the arterioles, capillaries and venules. The main tasks of the microcirculation 
are to ensure adequate oxygen delivery to meet the oxygen demands of cells in the 
tissue, and to regulate tissue perfusion to maintain tissue homeostasis. The 
microcirculation also has important functions in regulating the distribution of fluid 
between the intravascular and extravascular compartments, and in temperature 
regulation4. 
The cardiac output is intermittently ejected from the heart, but this is converted to a 
continuous, pulsatile flow by the elastic nature of the aorta and the large arteries. The 
arterioles have abundant smooth muscle in their walls, and are the main site where SVR 
is regulated. Moreover, the arterioles regulate the distribution of CO between different 
organs and contribute to the control of capillary hydrostatic pressure. The pulsatile flow 
seen in large arteries is dampened and intravascular pressure is reduced in the 
arterioles, making blood flow continuous when it reaches the capillaries. The capillary 
wall consists of a single layer of endothelial cells, and capillaries provide a large 
surface area for the exchange of oxygen and nutrients between tissues and blood. The 
capillaries are also the main site for regulation of the distribution of fluid between the 
intravascular and extravascular compartments. The main determinants of capillary 
blood flow are arteriolar tone, driving pressure, haemorheology, and capillary patency. 
The small veins and larger venules serve as elastic capacitance vessels, maintaining 
cardiac filling pressures. Postcapillary resistance in venules also contributes to the 
regulation of capillary hydrostatic pressure.    
THE GUT  
In man, the small intestine is divided into three structural parts; duodenum, jejunum 
and ileum. Besides being the main site for food digestion and nutrient absorption, the 
small intestine also has important immunological functions, and contains the gut-
associated lymphatic tissue (GALT), the largest lymphatic organ in the body. The large 
intestine, the colon, is the main site for water absorption in the intestines.   
In the small intestinal wall, the mucosa is mainly responsible for the absorption of 
nutrients and for maintaining gut barrier function. The absorptive surface is increased 
through circular folds of mucosa and submucosa, called plica circulares, with finger-
like mucosal projections, called villi. The villi epithelial cells also display numerous 
small protrusions, called microvilli, further increasing the area available for absorption. 
Between the villi are small openings of tubular glands in the mucosa, called the 
intestinal crypts. The small intestinal mucosa also contains a layer of loose connective 
tissue, the lamina propria, and a thin muscular layer, the muscularis mucosae. The 
submucosa is located beneath the muscularis mucosae, and contains large arterial and 
venous plexuses. Below the submucosa is the muscularis, containing an inner circular 
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and an outer longitudinal smooth muscle layer. The muscularis is responsible for 
intestinal propulsive motion. A thin layer of loose connective tissue, the serosa, covers 
the muscular layer. 
In man, the duodenum is supplied with blood from the coeliac trunk and the superior 
mesenteric artery supplies the jejunum, ileum and proximal and transversal parts of the 
colon, while the inferior mesenteric artery supplies the distal part of the colon and the 
rectum. Blood vessels supplying the small intestinal wall penetrate the muscularis and 
form a large vascular plexus in the submucosa. Branches from the submucosal plexus, 
together with serosal arterioles, supply the muscularis layer. From the submucosa, 
arterioles also extend though the muscularis mucosae and the lamina propria into the 
villi where a capillary network is formed. Venules arise from the capillary network at 
the top of the villi and run in the opposite direction from the arteriole, reaching the 
venous plexus of the submucosa. Venous blood from the small intestine is collected in 
the superior mesenteric vein, which drains into the portal vein.  
The particular vascular arrangement in the small intestinal mucosa, with each villus 
being perfused by a central arteriole in close proximity to the returning venule, results 
in a counter-current exchange where oxygen diffuses from the arteriole to the venous 
side. Due to this counter-current mechanism, PO2 is progressively lowered towards the 
tip of the villus. In normal conditions, the PO2 at the tip of the villus is as low as 2.0-3.3 
kPa, decreasing even further during low-flow states5. This anatomical arrangement 
makes the villi particularly vulnerable to hypoperfusion6.  
Intestinal microcirculation 
The mucosa and submucosa receive most of the small intestinal blood flow, 60-90%7,8. 
The villi receive approximately 30% and the crypts approximately 25% of total 
intestinal blood flow in resting conditions8. The arterial supply to the mucosa and 
muscularis layers is arranged in parallel, allowing for independent control of flow to 
these two layers. A decrease in perfusion pressure normally leads to a redistribution of 
intestinal blood flow towards the mucosa, and particularly the villi9, presumably a 
defence mechanism preserving mucosal barrier function. On the contrary, an increase 
in venous pressure redistributes blood flow towards the muscularis layer10.  
Blood flow in the small intestine is regulated by several different mechanisms: 
 When oxygen supply does not meet oxygen demand, vasodilating metabolites 
are released to the interstitium, increasing blood flow and oxygen supply. K+, 
H+, adenosine and osmolality are among the factors proposed as mediators of 
this local metabolic control of flow. 
 The arterioles exert a myogenic control of flow through their ability to constrict 
as a response to an increase in transmural pressure, and dilate when transmural 
pressure decreases (the Bayliss effect). This is the main mechanism behind the 
pressure-flow autoregulation seen in the intestine. However, this pressure-flow 
A. Andersson 
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autoregulation is a considerably weaker phenomenon than the autoregulation of 
renal blood flow.  
 Activation of the sympathetic nervous system reduces intestinal blood flow 
through α1-receptor stimulation inducing arteriolar constriction. However, when 
nerve activation is continued, flow is gradually recovered, a pattern called the 
autoregulatory escape from sympathetic stimulation. When the sympathetic 
nerve stimuli cease, there is a short period of hyperaemia before flow returns to 
normal. Local release of adenosine is an important factor contributing to the 
autoregulatory escape11. The autoregulatory escape is strongest in the villous 
part of the mucosa12. 
 Circulating vasoactive substances influence the intestinal microcirculation, for 
instance, both angiotensin II and vasopressin are potent vasoconstrictors in the 
intestinal wall. Circulating norepinephrine also induces vasoconstriction 
followed by an autoregulatory escape phenomena. 
 Intestinal capillary pressure and transcapillary fluid flux are regulated through a 
complex interplay between arterioles, precapillary sphincters, and venules.  
Capillary haematocrit is normally lower than systemic haematocrit. In small vessels, 
red cells tend to move away from the vessel wall and occupy the axial stream, leaving a 
relatively cell-free layer close to the vessel wall. At vessel branching points, the 
distribution of haematocrit between the two branches can be uneven, with the smaller 
branch receiving blood with a relatively lower haematocrit, a phenomenon called 
plasma skimming13,14. The vascular arrangement in the intestinal mucosa, with 
arterioles branching of from the submucosal plexus at a right angle, increases the 
degree of plasma skimming. This results in a relatively lower capillary haematocrit in 
the intestinal mucosa compared to the muscularis layer13.  
THE LIVER 
The liver serves a wide range of functions in the human body, including important 
metabolic functions, immunological functions, the synthesis of a variety of proteins, 
drug metabolism, and filtration of venous blood from the splanchnic area.  
The blood supply to the liver is somewhat unique in its dual supply from the portal vein 
and hepatic artery. The liver receives approximately 25% of cardiac output, 75-80% of 
this through the portal vein and 20-25% through the hepatic artery. However, due to 
lower oxygen saturation, the portal vein only delivers 50-60% of basal oxygen supply, 
40-50% being supplied by the hepatic artery.  
The pressure-flow autoregulation of the hepatic artery is weak, making the relationship 
between pressure and flow approximately linear below systolic arterial pressures of 80 
mmHg15. Flow in the portal vein is determined by the outflow from the extrahepatic 
splanchnic organs. In normal conditions, the liver is to some extent protected from 
hypoperfusion through the hepatic arterial buffer response16. When portal vein flow is 
            Introduction 
  5 
reduced, liver perfusion is preserved through an adenosine-dependent hepatic artery 
vasodilation increasing hepatic artery blood flow. Conversely, when portal vein flow 
increases, hepatic artery flow decreases.  
The portal venules and the hepatic arterioles run parallel to each other in the liver, 
forming the portal triads together with bile ducts, and supplying the blood to the 
sinusoids. The sinusoids correspond to the capillary bed of the liver, and constitute a 
low-pressure system where the supply of nutrients and removal of metabolic products 
takes place. The endothelium of the sinusoids is highly fenestrated, and separated from 
the hepatocytes by the space of Disse. After flowing through the sinusoids, the blood 
drains into central hepatic venules, and is finally collected in the hepatic veins16. The 
hepatic sinusoidal microcirculation is locally regulated by a critical balance between 
vasodilating agents, like nitric oxide and carbon monoxide, and vasoconstrictive agents, 
like endothelin-117. 
SEPSIS 
Definitions and epidemiology 
The definitions of sepsis, severe sepsis and septic shock have been under debate over 
the years. In 1992 a consensus was reached by a panel of experts at the Consensus 
Conference of American College of Chest Physicians/Society of Critical Care Medicine 
(ACCP/SCCM)18. Sepsis was defined as a systemic inflammatory response to a 
confirmed or suspected infection; severe sepsis as sepsis with organ dysfunction; and 
septic shock as sepsis with hypotension, despite adequate fluid resuscitation (Table 1). 
 
 
The incidence of severe sepsis ranges from 0.1319 to 3.020 per 1000 between studies 
using different methods and from different geographic areas. In Finland, the incidence 
of ICU-treated patients with severe sepsis was found to be 0.38 per 100021, and in a 
Table 1.
Definitions of sepsis (simplified from Bone et al
18
)
Systemic inflammatory A systemic inflammatory response elicited by a variety of 
response syndrome (SIRS) clinical insults. Includes ≥ 2 of the following findings:
▪ Body temperature >38 or <36 ºC
▪ Heart rate >90 beats per minute
▪ Respiratory rate >20 breaths per minute or PaCO2 <4.3 kPa
▪ Leukocytes >12 or <4·10
9
·L
-1
, or >10% immature cells
Sepsis SIRS and confirmed or suspected infection.
Severe sepsis Sepsis and signs of organ dysfunction, hypoperfusion or 
hypotension.
Septic shock Severe sepsis and persistent hypotension despite adequate  
fluid resuscitation.
A. Andersson 
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recent Swedish study the incidence of severe sepsis in 2005 varied from 0.13 to 0.43 
per 1000 depending on the criteria used for the diagnosis19.  The incidence of severe 
sepsis also seems to be increasing over time19. Severe sepsis and septic shock are 
common in patients admitted to the ICU; the prevalence of severe sepsis in the ICU has 
been estimated to be 11% in Germany22 and 10.5% in Finland21. Despite intense efforts 
to improve outcome mortality remains high, hospital mortality ranging from 22.1 to 
55.2% in European conditions19,21,23. Among factors that have been associated with 
increased mortality are age, renal failure, number of organ failures, comorbidities and 
race. 
During the past decades, gram-negative sepsis has decreased, while the incidence of 
gram-positive bacteria, polymicrobial infections and fungal infections has increased. 
Moreover, infection with multi-resistant bacteria constitutes a growing problem 
worldwide.   
Pathophysiology 
Septic shock primarily reflects a dysregulated immune response by the body to a 
microbial pathogenic insult, but the pathophysiology of sepsis is complex and not yet 
fully understood.  
The innate immune system constitutes a non-specific, early response system, detecting 
and reacting to pathogens in a rapid and powerful way. Innate immunity is considered 
to play a crucial role in the development of severe sepsis, and also has important 
functions in the activation and modulation of later antigen-specific, adaptive immune 
responses. The adaptive immunity has a slower onset, but the memory function of the 
adaptive immune system triggers faster and more powerful reactions after every new 
exposure to a particular pathogen. Recent studies indicate that the cholinergic nervous 
system, and in particular the vagus nerve, also is involved in the regulation and 
limitation of the septic inflammatory response through activation of α7cholinergic 
receptors on macrophages24. 
The initial event in severe sepsis and septic shock is the interaction between an 
invading pathogenic threat and the innate immune system. Cells of the innate immune 
system detect and react to invading microbes through specific receptors called pattern-
recognition receptors (PRRs). These PRRs can recognize both pathogen-associated 
molecules (pathogen-associated molecular patterns, PAMPs), and endogenous, 
intracellular proteins released following host tissue injury (damage-associated 
molecular patterns, DAMPs). Lipopolysaccharide (LPS), also called endotoxin, is a 
component of the gram-negative bacterial cell wall considered to be an important 
PAMP. Endotoxin activates the innate immune system through binding to toll-like 
receptor 4, an important PRR. The activation of PRRs triggers the production and 
release of inflammatory mediators, mainly through activation of the intracellular 
transcription factor NF-κB, and thereby promotes systemic and local 
inflammation25,26. 
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A prominent feature of septic shock is the upregulation of inducible nitric oxide 
synthase (iNOS) with increased production of nitric oxide (NO), resulting in 
generalized vasodilation. Plasma levels of the potent vasoconstrictor endothelin-1 
(ET-1) are also increased in septic shock. Moreover, plasma levels of ET-1 have been 
correlated to mortality and morbidity in septic patients27,28, indicating a role for the 
endothelin system in the pathophysiology of septic shock. 
The initial activation of the immune system results in an early, hyperactive 
inflammatory response with activation of endothelial cells and leukocytes, increased 
capillary permeability, and activation of coagulation and the complement system. In 
the tissues, the septic inflammatory response induces both microcirculatory and 
mitochondrial dysfunction, hypothesized to be the two main factors behind septic 
organ failure29. Besides being the energy suppliers of cells, mitochondria are also 
involved in oxygen sensing and cell death-signalling pathways (necrosis and 
apoptosis). Disturbances of oxidative phosphorylation within the mitochondria have 
been observed in both septic patients and animal models of sepsis30.  
 
 
Figure 1. An overview of the host-pathogen interaction in sepsis. PAMPs, pathogen-
associated molecular patterns; DAMPs, damage-associated molecular patterns; TLRs, 
toll-like receptors. Reproduced with permission from van der Poll and Opal, Lancet 
Infect Dis 2008; 8: 32–43.  
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After the initial proinflammatory response, an anti-inflammatory immune response 
with toll-like receptor suppression and an increased apoptosis of immune cells may 
follow. This phenomenon is considered to be the main factor behind the increased 
susceptibility to secondary infections seen in patients with septic shock. 
An overview of the immune response in sepsis is presented in Figure 1. 
Sepsis and the microcirculation 
Currently, goal-directed septic shock therapy is mainly guided by systemic 
haemodynamic variables. Protocol-driven treatment of septic shock has improved 
mortality, but even though global haemodynamic goals are met, there is still a 
considerable mortality among septic shock patients31. In recent years, microcirculatory 
changes have been highlighted as an important part of the pathophysiology of severe 
sepsis and septic shock2. Several studies have confirmed the presence of severe 
microcirculatory disturbances in septic shock patients3,32, and the presence and 
persistence of such abnormalities have been found to be associated with morbidity and 
mortality in patients3,33. These findings indicate that incorporating therapies targeting 
the microcirculation into goal-directed septic shock treatment could be of value. 
The relationship between septic microcirculatory alterations and changes in systemic 
and regional indices of flow and pressure is still under debate, but there seems to be a 
poor correlation between systemic haemodynamic variables and microcirculatory 
changes in sepsis, and microcirculatory failure can occur in the presence of adequate 
values for central haemodynamics and oxygen delivery34. Results from both animal 
studies and patients also indicate that there is heterogeneity in microcirculatory 
alterations between different vascular beds35,36.  
During severe sepsis, all microcirculatory components are severely disturbed, leading 
to loss of the microcirculatory autoregulation of blood flow. The microcirculatory 
changes in sepsis are summarized in Figure 2. The inflammatory response induces 
systemic activation of the endothelium and endothelial cell swelling and dysfunction. 
The endothelium has an essential role in vasomotor regulation and integration in the 
microcirculation, and endothelial dysfunction with loss of the normally precise local 
control of microvascular flow is considered to be a pivotal factor in the development of 
sepsis-induced microcirculatory failure. Endothelial activation also results in the 
expression of proadhesive and procoagulant factors, and in increased vascular 
permeability2. Activated leukocytes adhere to the endothelium, penetrate the vascular 
barrier and release reactive oxygen species further damaging the microcirculation. 
Moreover, increased leukocyte rolling and aggregation in venules contributes to 
microcirculatory flow impairment37. Capillary clotting is increased due to an impaired 
ability of red blood cells to deform in the capillaries, leukocyte aggregation, and 
activation of coagulation with deposition of platelet/fibrin clots37.  
NO has a pivotal role in the local control of microcirculatory blood flow, but the NO 
system is severely disturbed in septic shock. iNOS is upregulated and total body NO 
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levels are increased, but iNOS is heterogeneously expressed within and between 
tissues, potentially creating localized areas of relative NO deficiency. Alterations in the 
NO system are thought to be a major factor contributing to the heterogeneity of tissue 
perfusion and microcirculatory shunting seen in septic shock38. The endothelial cell 
production of endothelin-1 is also greatly increased in sepsis, and ET-1-induced 
vasoconstriction in the microcirculation has been proposed as an important cause of 
microcirculatory failure in sepsis39.   
 
 
 
The microcirculatory abnormalities seen in severe sepsis and septic shock typically 
include increased heterogeneity of microvascular flow, an increased number of 
stopped-flow microvessels, a decreased microvascular flow velocity, and a lowered 
functional capillary density40. The sepsis-induced heterogeneity of flow is important, 
since tissues tolerate a homogenous decrease in blood flow better than a heterogeneous 
one41. The maldistribution of blood flow at the capillary level results in hypoxic areas 
in the microcirculation due to an increased diffusion distance for oxygen41, and in 
shunting of oxygen from the arterial to the venous compartment. This inability to match 
oxygen delivery to oxygen demand in the tissue leads to tissue hypoxia, and persistence 
EC dysfunction NO ↑ RBCs Leukocytes Activated coagulation
▪ Loss of vasomotor ▪ iNOS induction ▪ Deformability ↓ ▪ Activation ▪ Platelet/fibrin clots
integration and control ▪ Aggregation ↑ ▪ Release of ROS
▪ Proadhesive ▪ Adhesion ↑
▪ Procoagulant
▪ Permeability ↑
▪ ET-1 ↑
                           MICROCIRCULATORY DYSFUNCTION
   ▪ Heterogeneity of flow ↑                              TISSUE HYPOXIA
            ▪ Oxygen diffusion distance ↑
            ▪ Shunting of oxygen ↑
            ▪ O2 supply/demand match ↓
           INFECTION
   ▪ Stopped flow capillaries ↑
   ▪ Microvascular flow velocity ↓
   ▪ Functional capillary density ↓
            SYSTEMIC INFLAMMATION
Figure 2. An overview of the microcirculatory alterations in sepsis. EC, endothelial cell; 
ET-1, endothelin-1; NO, nitric oxide; iNOS, inducible nitric oxide synthase; RBCs, red 
blood cells; ROS, reactive oxygen species. 
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of microcirculatory dysfunction has been proposed as the leading cause of organ failure 
in severe sepsis and septic shock42.   
Sepsis and the gut 
The gut has long been presumed to have an important role in the pathogenesis of 
multiple organ dysfunction in critical illness and septic shock. As early as the 1960s, 
experimental studies showed that gut bacteria and endotoxins could gain access to the 
systemic circulation in shock states43,44, a process later termed bacterial translocation. 
In the 1980s, the idea of septic states originating from commensal gut bacteria 
penetrating the intestinal wall, with the gut acting as the motor of multiple organ 
dysfunction, gained clinical attention45. The increased intestinal permeability seen in 
critical illness has been associated with an increased risk of complications, multiple 
organ dysfunction syndrome, and mortality46-49. Still, the clinical relevance of bacterial 
translocation has remained controversial, mostly due to the failure to consistently find 
gut-derived bacteria or endotoxins in the blood or mesenteric lymph nodes of critically 
ill patients50,51. Recently, there has been a growing understanding that the role of the 
gut in sepsis is more complex, and that it is not only limited to the notion of commensal 
gut bacteria reaching the systemic circulation52. The gut has important immunological 
functions, and recent studies indicate that during conditions associated with gut 
hypoperfusion, the gut itself can become a source of inflammatory and tissue injurious 
factors. Magnotti et al. showed that systemic inflammation and distant organ injury can 
be induced by nonbacterial, proinflammatory factors released from the ischaemic gut 
into the mesenteric lymphatics53, a concept termed the gut-lymph hypothesis54.   
Current theories on how the gut contributes to the development of systemic 
inflammation and multiple organ dysfunction syndrome include both translocation of 
bacteria or toxins to the systemic circulation, and the release of gut-derived, 
proinflammatory factors into the circulation and the mesenteric lymphatics52.  
Gut microcirculation in sepsis 
Gut microcirculatory disturbances are present early in experimental septic shock36, and 
include a decreased percentage of perfused villi, a reduction of mean erythrocyte 
velocity and functional capillary density, and an increased heterogeneity of flow55. Due 
to the combination of the counter-current oxygen exchange, making the tip of the villi 
prone to hypoxia, and the high metabolic demand in the intestinal mucosa, the mucosa 
is particularly vulnerable to microcirculatory disturbances. In septic shock, 
microcirculatory failure has been proposed as the main factor behind gut mucosal 
acidosis56. Moreover, microcirculatory hypoperfusion could contribute to the increased 
intestinal wall permeability seen in sepsis. A better knowledge of the factors 
contributing to sepsis-induced gut microcirculatory failure is needed, and therapies 
restoring gut microcirculatory perfusion could potentially be of major importance in the 
treatment of sepsis. 
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Sepsis and the liver 
The liver is an important modulator of the systemic inflammatory response in sepsis. 
Kupffer cells, the largest mass of macrophages in the body, act as scavengers for 
systemic and gut-derived inflammatory mediators and cytokines57, and also clear the 
portal vein blood of bacteria58and endotoxins59. However, when activated, Kupffer cells 
also produce proinflammatory mediators, thereby contributing to the development of 
systemic inflammation60. The liver also plays a major role in metabolism and protein 
synthesis, and in sepsis, the hepatocytes increase synthesis and release of coagulation 
factors, complement factors, and acute-phase proteins61. 
In patients with septic shock, the development of acute liver failure has been associated 
with increased mortality. Sepsis-induced liver failure can be divided into an early, 
primary dysfunction followed by a later, secondary dysfunction61. The primary 
dysfunction is usually related to shock and hypoperfusion, and hepatic function is often 
severely compromised. The secondary dysfunction is more insidious. Although most of 
the hepatic functions remain intact, this secondary dysfunction can cause spillover of 
bacteria, endotoxin, and inflammatory mediators, possibly promoting systemic 
inflammation.  
Microvascular dysfunction and ischaemia are considered to be main factors behind the 
hepatic dysfunction seen in sepsis62. Also, the hepatic arterial buffer is impaired in 
endotoxaemia, making the liver more vulnerable to hypoperfusion63. Other factors 
contributing to liver damage in sepsis is mitochondrial dysfunction, an increase in 
hepatocyte apoptosis, and tissue damage mediated by activated neutrophils.  
Initial treatment of severe sepsis 
In recent years, the concept of early recognition and aggressive goal-directed treatment 
of severe sepsis has been widely accepted. In 2001, Rivers et al. demonstrated an 
improved survival in patients with severe sepsis or septic shock treated with early goal-
directed therapy (EGDT) compared to patients treated with standard therapy64. A 
simplified version of the EGDT protocol used by Rivers et al. is presented in Figure 3.  
In 2002, the European Society of Intensive Care Medicine, the International Sepsis 
Forum, and the Society of Critical Care Medicine launched the Surviving Sepsis 
Campaign (SSC). The SSC is an international campaign to improve outcome in severe 
sepsis and septic shock through the implementation of evidenced-based guidelines and 
treatment protocols.  
The implementation of EGDT seems to improve the prognosis of septic shock 
patients65, but even though the haemodynamic goals of the treatment protocols are met, 
tissue hypoperfusion can still persist, eventually leading to organ failure and death31. 
Interestingly, Sakr et al. found that sublingual microcirculatory alterations was a better 
prognostic indicator than global haemodynamic variables in septic patients3. Moreover, 
recent findings indicate that early increases in microcirculatory blood flow during 
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EGDT are associated with reduced organ failure in septic patients without substantial 
differences in global haemodynamics33. Based on the accumulating data indicating the 
importance of microcirculatory failure in sepsis, the direct monitoring of 
microcirculatory perfusion and the incorporation of therapies targeting the 
microcirculation into EGDT protocols has been proposed as a new strategy in the 
treatment of severe sepsis.   
 
 
Besides the early administration of correct antibiotics, the SSC resuscitation bundle for 
the first 6 hours also includes EGDT using intravenous fluids, vasoactive substances 
and transfusion of red blood cells to reach predefined haemodynamic goals66.  In septic 
shock, the systemic hypotension can lead to a loss of the pressure-flow autoregulation 
in various vascular beds, and organ blood flow can become linearly dependent on 
perfusion pressure. What level of MAP that should be targeted to preserve organ 
perfusion has still not been clearly defined, but the SSC guidelines recommend 
targeting a MAP of 65 mm Hg66. Norepinephrine and dopamine are first-line 
vasopressors to treat persistent hypotension in spite of adequate fluid resuscitation, 
although concerns have been raised that vasopressors can induce an excessive 
Figure 3. A simplified version of the protocol for early goal directed 
therapy used by Rivers et al. Reproduced with permission from Daniels et 
al., Emerg Med J, 2010. 
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vasoconstriction in the microcirculation67, thereby worsening tissue hypoperfusion 
rather than improving it. A better understanding of the role of hypotension in the 
development of septic microcirculatory derangements, and of the microcirculatory 
effects of perfusion pressure manipulation, could be of significant value for improving 
septic shock treatment. 
 
Animal models of sepsis 
Studies using invasive monitoring to investigate sepsis pathophysiology and 
preliminary studies investigating unproven pharmacological interventions cannot be 
performed in humans for ethical reasons, necessitating the use of animal models.   
The infusion of endotoxin has been extensively used in animal models to mimic the 
septic response in patients. Although an endotoxin infusion is not identical to the 
complex situation of sepsis, endotoxin is an important part of the pathophysiology of 
gram-negative sepsis, and the administration of small doses of endotoxin to human 
volunteers induce haemodynamic, metabolic and haematologic changes that are 
qualitatively similar to those seen in septic patients68. Endotoxin is easy to use, and 
doses are readily measured and controlled. The response to endotoxaemia is also easy 
to replicate, facilitating comparisons between groups68,69.  
A large number of animal species have been used in sepsis models. Rats and mice are 
inexpensive to purchase and maintain, and are often used when a large number of 
animals are needed for the experiment. However, in many ways rodents are 
physiologically and pharmacologically different from humans, among other things 
being considerably more resistant to the effects of endotoxin. The size of rodents also 
limits the possibilities for monitoring and blood sampling68. The sensitivity of pigs and 
sheep to endotoxin is more similar to that of humans, and their size makes extensive 
surgical preparation and monitoring possible. Pigs are similar to humans in renal, 
cardiovascular and intestinal physiology and anatomy70, and have been extensively 
used in sepsis models. In short-term models of endotoxaemia, pigs normally develop a 
hypodynamic circulatory response, but this can be converted to a hyperdynamic 
circulation through heavy fluid loading. The sheep is a docile animal, having the 
advantage that studies can also be performed in unanaesthetized animals. Moreover, 
sheep are also prone to developing a hyperdynamic response, similar to that seen in 
septic patients, when infused with endotoxin71.  
ETHYL PYRUVATE 
Besides having a central role in intermediary metabolism, pyruvate also functions as a 
scavenger of reactive oxygen species. However, the possibility to use pyruvate as a 
therapeutic agent is limited by its poor solubility in solution. To improve its solubility, 
Sims et al. used the ethyl ester of pyruvic acid, ethyl pyruvate (EP), in a balanced salt 
solution called Ringer’s ethyl pyruvate solution (REPS)72. Treatment with EP was 
shown to ameliorate gut mucosal injury in a rat model of ischaemia and reperfusion, 
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and in subsequent studies EP was found to have positive effects on intestinal barrier 
function73, renal function74, and survival75,76 in small animal models of endotoxaemia 
and sepsis.  
EP is a potent anti-inflammatory agent, decreasing NFκB-activation and the release of 
proinflammatory cytokines as HMGB-177. It has also been suggested that pyruvate 
have direct inotropic effects through glycolytic substrate augmentation, and initial 
studies with EP indicated positive effects on cardiac function78 and gut 
microcirculation79 in small animal models of cardiac ischaemia78 and mesenteric 
ischaemia and reperfusion79. Given the results from initial small animal models of 
sepsis, it was of interest to further evaluate the potential role of EP as a therapeutic 
agent in sepsis, using a large animal model to investigate the effects of EP on systemic 
haemodynamics and splanchnic perfusion. 
THE ENDOTHELIN SYSTEM 
Endothelin-1 (ET-1) was originally identified in 1988 as a vasoconstrictive peptide 
released from the endothelium80. Later studies isolated two additional isoforms 
belonging to the endothelin (ET) family, endothelin-2 and endothelin-3. ET-1 is the 
predominant form of the endothelins, and it is considered to be the most important 
isoform in human physiology and pharmacology.  
ET-1 synthesis and secretion 
The peptide ET-1 is 21 amino acids long, and the most potent vasoconstrictor in the 
human body so far known. ET-1 is synthesized through enzymatic cleaving of 
precursor proteins. Initially, the primary peptide pre-pro-ET-1 is cleaved by 
endopeptidases to big ET-1, a peptide with weaker vasoconstrictive properties. Finally, 
big ET-1 is cleaved by endothelin-converting enzymes, resulting in active ET-181. The 
production occurs mainly in endothelial cells, from which ET-1 is continuously 
released, contributing to the maintenance of vasomotor tone82. In the endothelial cell, 
ET-1 is also stored in intracellular storage granules. Among the factors known to 
stimulate ET-1 synthesis and release are proinflammatory cytokines, endotoxin, 
catecholamines, hypoxia, thrombin, angiotensin II, growth factors, and ET-1 itself83,84. 
Factors inhibiting ET-1 production include ANP, prostaglandins, NO, and heparin84,85. 
Eighty per cent of ET-1 is secreted abluminally by the endothelial cells, acting on 
underlying smooth muscle cells. ET-1 mainly acts as a paracrine and autocrine 
mediator, and in normal conditions circulating levels of ET-1 are low. However, in 
some pathological conditions, such as sepsis, plasma levels increase dramatically, and 
ET-1 may then also have endocrine properties86. 
Besides vascular effects, ET-1 exerts a number of physiological functions in the human 
body, and the effects of the endothelin system have been extensively reviewed 
elsewhere87. Release of ET-1 has also been associated with the development of sepsis, 
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vascular disease, heart failure, diabetes, pulmonary hypertension, and several other 
pathological conditions. 
Endothelin receptors 
In humans, ET effects are mediated by two subtypes of G protein-coupled endothelin 
receptors, the endothelinA (ETA) and endothelinB (ETB) receptors. The ETA receptor is 
primarily expressed on vascular smooth muscle and mediates vasoconstriction. The 
actions of the ETB receptor are more complex and dependent on the location of the 
receptor. ETB receptors located on vascular smooth muscle cells mediate 
vasoconstriction, but ETB receptors on endothelial cells induce vasodilation through the 
release of nitric oxide and prostacyclin88. There is also evidence of the existence of a 
crosstalk between ETA and ETB receptors, possibly through receptor 
heterodimerization89. 
Stimulation of ETA receptors and vasoconstrictive ETB receptors activates 
phospholipase C which in turn activates the second messengers diacylglycerol (DAG) 
and inositol triphosphate. This results in an increase of cytosolic calcium, inducing 
smooth muscle contraction and vasoconstriction90. ET-1 generally induces a more 
powerful vasoconstriction in veins than in arteries91. Since ET-1 receptors mediate both 
vasodilation and vasoconstriction, the net effect of ET-1 in a vascular bed depends on 
the properties of the local receptor population.   
The ETB receptor also functions as a clearance receptor, removing circulating ET-1 
from the circulation via endocytosis92. The plasma half-life of ET-1 is approximately 1-
2 minutes93. The pulmonary circulation is the main site for ET-1 removal94, but the 
kidney and liver also contributes to the clearance of ET-1. 
ET-1 in sepsis 
Levels of ET-1 are increased in all forms of shock, but they are particularly high in 
septic shock. The increased plasma levels of ET-1 also correlate with increased 
mortality and morbidity in septic patients27,28. Besides vascular effects, ET-1 increases 
the activation and adhesion of leukocytes95 and induces production of reactive oxygen 
species96, thereby contributing to the proinflammatory response in sepsis. In septic 
shock, ET antagonists have been shown to have beneficial effects on haemodynamics97, 
pulmonary hypertension97, acute lung injury98, renal failure99, and hepatosplanchnic 
hypoperfusion100. Most of these data originate from the use of ET receptor antagonists 
in animal models of septic or endotoxaemic shock.  
Intestinal effects 
In models of endotoxaemic shock, mixed endothelin receptor antagonism with 
bosentan effectively restores portal vein flow and improves intestinal mucosal 
acidosis100, demonstrating positive effects on hepatosplanchnic circulation.   
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ET-1 has been implicated as one of the possible mediators of the microcirculatory 
failure seen in the gut in sepsis. In 1993, Wilson et al. demonstrated that an infusion of 
anti-endothelin antibodies improves intestinal microcirculation in a rat model of 
bacteraemia39. In a model of porcine septic shock, Krejci et al. found that the mixed 
endothelin receptor antagonist bosentan improved microcirculation in the gastric and 
colonic mucosa, but a significant difference in microcirculatory flow in the jejunal 
mucosa and muscularis could not be demonstrated101.  
Selective ETA receptor antagonism has previously been demonstrated to improve 
intestinal microvascular blood flow in a rat model of endotoxaemia102. This finding 
indicates that the ETA receptor could be the main receptor responsible for the ET-1-
induced vasoconstriction in the intestine, but the knowledge of how the different ET 
receptors influence intestinal microcirculation in sepsis is still incomplete.  
There are several mechanisms by which ET-1 could affect the intestinal 
microcirculation. Intravenous infusion of ET-1 decreases intestinal mucosal functional 
capillary density and red blood cell velocity103, and also causes increased leukocyte 
activation and aggregation in the intestinal microcirculation, thereby increasing 
microvascular thrombosis104. ET-1 is a powerful venous vasoconstrictor, and increases 
portal vein pressure in endotoxaemia105. An increase in portal vein pressure has been 
shown to divert blood away from the intestinal mucosa towards the muscularis10, 
possibly contributing to mucosal hypoperfusion in sepsis. Moreover, ET-1 can 
contribute to the development of tissue oedema through an increase in endothelial 
permeability106, reduced lymphatic flow107, and increased venous pressure. 
Hepatic effects 
Hepatic sinusoids contract in response to stimulation of ETA and ETB receptors, but 
ETB receptors also induce vasodilation through activation of the endothelial NO 
synthase system. Studies in rat models have indicated that ET-1 is an important factor 
contributing to hepatic microcirculatory failure in sepsis and endotoxaemia. ET-1 has 
been shown to increase portal venous resistance and portal vein pressure through 
elevation of both sinusoidal and presinusoidal resistance in the portal circulation108. 
Furthermore, the portal circulation was found to have an increased vascular 
responsiveness to ET-1 in rat sepsis109. In line with this, the mixed endothelin receptor 
antagonist tezosentan has been found to decrease liver injury in small animal models of 
endotoxaemia110,111 and sepsis111. Previous studies investigating the role of the different 
ET receptors in mediating hepatic microcirculatory effects in intact animals in sepsis 
are very sparse, but the selective ETA receptor antagonist BQ-485 was found to have 
detrimental effects on liver microcirculation in a rat model of endotoxaemia112. 
Moreover, studies investigating effects of selective ETA receptor antagonism on liver 
injury in endotoxaemia have yielded conflicting results113,114.  
            Introduction 
  17 
In contrast to the positive hepatic effects seen with endothelin receptor antagonism in 
rat models, Krejci et al could not demonstrate a significant improvement of hepatic 
microcirculatory perfusion using bosentan in a porcine model of fecal peritonitis101. 
Also, tezosentan failed to improve hepatic microcirculation and liver injury in a murine 
model of systemic inflammation115.  
In conclusion, the role of ET-1 and the different ET receptors in the development of 
hepatic microcirculatory failure in sepsis and endotoxaemia is still under debate, and 
data from large animal models are still scarce. 
NOREPINEPHRINE 
In fluid resuscitated patients, norepinephrine infusion is a first-line treatment for septic 
hypotension. Norepinephrine increases mean arterial pressure and systemic perfusion 
pressure through α1 receptor-mediated vasoconstriction in arterioles, leading to an 
increase in systemic vascular resistance. Norepinephrine also has positive inotropic and 
chronotropic effects through its effects on cardiac β1 and β2 receptors, and increases 
venous return through constriction of venous capacitance vessels, thereby increasing  
cardiac preload. The cardiac effects of norepinephrine usually lead to an increased 
cardiac output in septic patients116, also contributing to the increase in MAP. 
Norepinephrine does not seem to impair splanchnic blood flow in septic shock 
patients117,118, but the existing data are limited.  The effects of norepinephrine on the 
intestinal microcirculation have been investigated in various animal models of sepsis, 
with different studies finding improved119, worsened67,120, or unaltered121,122 
microcirculatory perfusion after norepinephrine administration.   
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AIMS 
 
The overall aims of the thesis were 
 
• To establish an experimental animal model, using endotoxin infusion to mimic 
the septic response, suited for studies investigating splanchnic microcirculatory 
changes. 
 
 
• To investigate changes in the splanchnic microcirculation in response to 
experimental endotoxaemia and to the following interventions aimed at 
improving the microcirculation:  
1. Ringer’s ethyl pyruvate solution 
2. Mixed endothelin and selective endothelinA receptor antagonists 
3. Increasing perfusion pressure with norepinephrine. 
 
 
• To investigate the relationship between splanchnic microcirculatory changes 
and changes in systemic haemodynamics and regional blood flow in different 
animal models of endotoxaemia. 
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METHODOLOGICAL CONSIDERATIONS 
ANIMALS 
In papers I-III, crossbred (Landrace/Yorkshire/Hampshire) female pigs weighing 28-37 
kg were used. Porcine and human splanchnic organs are anatomically and 
physiologically similar69, and the size of the pig allows for the necessary 
instrumentation and blood samples. The ET system is also similar between pigs and 
humans123. 
In paper IV, ewes weighing 47±6 kg were used. Long-term (≥24 hours) sheep models 
of endotoxaemic shock provide a suitable animal model reproducing many of the 
pathophysiologic features found in septic patients, including a hyperdynamic syndrome 
and multiple organ dysfunction124. 
All experimental protocols were approved by the ethics committee for experiments in 
animals, Stockholm, Sweden, and all studies were conducted in accordance with the 
European Convention for Protection of Vertebrate Animals Used for Experimental and 
Other Scientific Purposes (Council of Europe No 123, Strasbourg 1985). 
ANAESTHESIA 
The porcine experiments 
In the porcine experiments (papers I-III) the animals were premedicated with ketamine 
10 mg·kg-1, midazolam 0.5 mg·kg-1, and atropine 0.05 mg·kg-1 intramuscularly. After 
cannulation of the marginal ear vein, anaesthesia was induced with propofol (40-80 
mg) and the animals were orally intubated. Anaesthesia was maintained with a 
combination of sevoflurane (2.6% end-tidal concentration during surgical procedures, 
followed by 1.0% end-tidal concentration throughout the experiment) and an infusion 
of fentanyl 10 mg·kg-1·h-1 and midazolam 0.15 mg·kg-1·h-1. Additional doses of fentanyl 
and midazolam were given if needed. Muscle paralysis was achieved by an infusion of 
pancuronium bromide 0.5 mg·kg-1·h-1. Before the administration of muscle relaxants, 
anaesthetic depth was ensured through pain stimulation of the fore hoof.  
The animals were mechanically ventilated; the settings of the ventilator were adjusted 
to reach an arterial PCO2 value of 4.7–5.3 kPa at baseline, and were then kept constant 
throughout the experiment. The body temperature was maintained at 37-39ºC by 
heating pads and blankets. After the surgical preparation, the animals were allowed 60 
minutes of rest before the endotoxin infusion was started. 
All animals received a continuous infusion of saline with glucose 25 mg·ml-1 at a rate 
of 20 ml·kg-1·h-1 during surgical preparation. In paper I, fluid therapy was modified 
according to the experimental protocol after 60 minutes of endotoxaemia. In paper II, 
the infusion was continued throughout the experiment. In paper III, an infusion of 
hydroxyethyl starch 130/0.4 (Voluven 60 mg·ml-1, Fresenius Kabi AB, Uppsala, 
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Sweden) at a rate of 10 ml·kg-1·h-1 was also given during surgical preparation. After the 
surgical preparation, the animals in paper III received 5 ml·kg-1·h-1 of saline with 
glucose 25 mg·ml-1 and 15 ml·kg-1·h-1 of Ringer’s acetate (RA) throughout the 
experiment. 
The sheep experiments 
In the sheep experiments anaesthesia was induced with intravenous sodium thiopental 
10 mg·kg-1 after cannulation of the external jugular vein. The animals were orally 
intubated and mechanically ventilated. A combination of isoflurane (2.0% end-tidal 
concentration during surgical procedures followed by 1.2-1.6% end-tidal concentration 
throughout the experiment) and an intravenous infusion of midazolam 0.1 mg·kg-1·h-1 
was used to maintain anaesthesia during the experiments. No muscle relaxants were 
administered. The settings of the ventilator were continually adjusted during the 
experiments aiming at an arterial PCO2 value of 4.8-5.7 kPa. After the surgical 
preparation, the animals were allowed 120 minutes of rest before the endotoxin 
infusion was started. All animals received a continuous infusion of RA 3 ml·kg-1·h-1, 
and bolus doses of hydroxyethyl starch 130/0.4 (Voluven 60 mg·ml-1, Fresenius Kabi 
AB, Uppsala, Sweden) were administered according to the experimental protocol.  
The surgical preparation and catheterization of the animals are described in detail in the 
separate papers of this thesis. An overview of the monitoring equipment used in papers 
I-IV is presented in table 2. 
 
 
 
Table 2. Paper I Paper II Paper III Paper IV 
(Pig) (Pig) (Pig) (Sheep)
Pulmonary artery catheter X X X X
Arterial line X X X X
PV flowprobe X X X
SMA flowprobe X X
RA flowprobe X
Mesenteric vein catheter X
Air tonometry ileum X X X
LD ileal mucosa X X X X
LD ileal muscularis X X X
LD liver X X X
LD colon mucosa X
LD renal cortex X
SDF ileal mucosa X
An overview of the monitoring equipment used in paper I-IV. PV, portal vein;   
SMAF, superior mesenteric artery; RA, renal artery; LD, laser Doppler; SDF,
sidestream dark field.
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ENDOTOXIN 
Escherichia coli lipopolysaccharide (LPS; serotype 0111:B4, Sigma-Aldrich Sweden 
AB, Stockholm, Sweden) was used in papers I-IV to induce a response similar to that 
seen in patients with severe sepsis. LPS, also called endotoxin, is a component of the 
gram-negative bacterial cell wall, and consists of a polysaccharide side chain, a core 
oligosaccharide, and a lipid component called lipid A. In the body, LPS interacts with 
CD14 and activates the toll-like receptor 4, subsequently initiating the transcription of 
proinflammatory genes and inducing pathophysiological changes similar to those seen 
in human gram-negative sepsis.  
In papers I-III, the LPS infusion was started at a rate of 0.31 µg·kg-1·h-1 and increased 
stepwise until reaching 2.5 µg·kg-1·h-1 after 30 minutes. In paper IV, the LPS infusion 
was started at a rate of 0.3 µg·kg-1·h-1 and subsequently adjusted according to the 
experimental protocol. 
PULMONARY ARTERY CATHETER 
In papers I-IV, a balloon-tipped pulmonary artery catheter (7.5 F Swan-Ganz; Edwards 
Lifesciences, Irvine, CA) was connected to a Vigilance Monitor system (Edwards 
Lifesciences), and used for continuous measurements of cardiac output (thermodilution 
technique), central venous pressure (CVP), mean pulmonary artery pressure (MPAP), 
mixed venous oxygen saturation (SvO2), and body temperature. The catheter was 
inserted through the right jugular vein, and positioned in the pulmonary artery by 
pressure guidance.  
ULTRASONIC FLOW PROBES 
Ultrasonic flow probes (Transonic Systems Inc., Ithaca, NY) were used to measure 
portal vein flow (papers I-III), renal artery flow (paper I) and superior mesenteric artery 
flow (papers III-IV). The flow probe has two ultrasonic transducers positioned on one 
side of the vessel and an acoustic reflector positioned on the opposite side of the vessel. 
One of the transducers is positioned upstream and one downstream from the reflector. 
The two transducers pass ultrasonic signals back and forth, alternately intersecting the 
flowing liquid in upstream and downstream directions, and the difference between the 
upstream and downstream integrated transit times is used to calculate a measure of 
volume flow in ml/min.  
MICROCIRCULATORY MEASUREMENTS 
Laser Doppler flowmetry 
Laser Doppler flowmetry (LD) was used to measure microcirculatory perfusion in the 
ileal mucosa (papers I-IV), ileal muscularis (papers 1, III-IV), liver (papers I-III), 
colonic mucosa (paper II), and renal cortex (paper I).  
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LD is an established method for the real-time measurement of microcirculatory 
perfusion in various tissues. The method is based on the measurement of the small 
frequency shift, the Doppler shift, which arises when a near-infrared laser light is 
scattered by moving red blood cells in the tissue. Monochromatic light is carried to the 
tissue by a fibre optic probe containing one emitting and one receiving fibre. In the 
tissue, the light is scattered and partly absorbed. When the light hits moving blood cells 
in the tissue there will be a change in wavelength, while the wavelength of light hitting 
static tissue structures is unchanged. The backscattered light is picked up by the 
receiving fibre, and the magnitude and frequency of the changes in wavelength are 
analysed to calculate the number and velocity of red blood cells in the tissue125.  
The tissue volume assessed by LD is hemisphere-shaped, but the exact sampling 
volume and measuring depth cannot be calculated. Depending on the properties of 
individual tissues, as, for instance, the structure and density of capillary beds, tissues 
will absorb and scatter light in different ways, and this influences measuring depth. The 
measuring depth also depends on the properties of the LD probe. An increase of the 
fibre diameter, the distance between the emitting and the receiving fibres, or the 
wavelength of the light will increase penetration depth126. The probes used in this thesis 
were standard probes (Perimed AB, Järfälla, Sweden), with a fibre separation of 0.25 
mm, a fibre diameter of 0.1 mm, and a wavelength of 780 nm.  
Since the measuring volume is unknown, it is not possible to obtain absolute values of 
blood flow expressed as ml·min-1·g tissue-1. Instead, values are obtained as arbitrary 
perfusion units (PU), reflecting the product of velocity and concentration of blood cells 
in the tissue sample, and the quantity measured with laser Doppler flowmetry is 
generally referred to as perfusion125. Results are presented as changes relative to 
baseline in percentage. Before the start of the experiments, the laser Doppler probes 
were calibrated according to the manufacturer’s instructions, at optical zero using a 
plastic disc and at 250 PU using motility standard latex solution. LD measurements 
were obtained and analysed using Perisoft for Windows data acquisition software 
(Perimed AB).     
Sidestream dark field imaging 
Sidestream dark field imaging (SDF) was used in paper IV to evaluate the 
microcirculation in the ileal mucosa. SDF is a recently introduced technique allowing 
the direct visualization of the microcirculation. The SDF consists of a light guide 
surrounded by a ring of stroboscopic light-emitting diodes (LEDs). The device utilizes 
a new method of reflectance avoidance. The LEDs at the tip of the device are optically 
isolated from the inner image-conducting core, thereby completely avoiding tissue 
surface reflections and permitting visualization of subsurface structures. The emitted 
light has a wavelength of 530 nm, a wavelength of light that is absorbed by 
haemoglobin in red blood cells, making red blood cells visible as dark globules. The 
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technique provides clear images of blood vessels in the microcirculation containing red 
blood cells, without the need for contrast dyes. 
In paper IV, an ileostomy was constructed, and SDF videos of the ileal mucosal 
microcirculation were obtained at baseline, after 24 hours of endotoxaemia, and after 
one hour of norepinephrine treatment. The SDF videos were obtained and analysed in 
accordance with previously published guidelines127. Due to the heterogeneity in 
microvascular flow seen in sepsis, steady SDF images of 10-20 seconds’ duration were 
acquired at three to five sites in the ileum at each time point. The videos were stabilized 
using the AVA 3.0 software (MicroVision Medical, Amsterdam, The Netherlands) and 
analysed blindly and in random order.  
Images were divided into four quadrants, and the microvascular flow index (MFI) was 
determined. MFI is a semiquantitative score of the types of microvascular flow 
predominantly seen in each quadrant. Type of flow in each quadrant is determined 
using an ordinal scale; 0, no flow; 1, intermittent flow; 2, sluggish flow; 3, normal flow. 
The MFI value was calculated as the average score of all quadrants at each time point. 
The heterogeneity index was calculated at each time point as the highest flow velocity 
minus the lowest flow velocity divided by the mean MFI across all mucosal sites at that 
time point, as previously described by Trzeciak et al128.  
In all videos, the number of villi was counted and all villi were semiquantitatively 
classified as perfused, heterogeneously perfused or unperfused. In every villus, areas 
containing vessels with continuous flow (MFI 2 and 3) were classified as perfused, and 
areas containing vessels without continuous flow (MFI 0 and 1) were classified as 
unperfused. The percentage of perfused villi was calculated at each time point as 
number of perfused villi per total number of villi visible. Figure 4 shows an image of 
the ileal villi microcirculation obtained from the SDFvideos. 
 
 
 
 
 
Figure 4. A still image of the ileal mucosal microcirculation obtained 
from the videos taken with the SDF technique. 
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TONOMETRY 
In papers II-IV a 14 F tonometry catheter (GE Healthcare Information Technologies 
AB, Stockholm, Sweden) for air tonometry was inserted into the lumen of the ileum 
through a small incision in the ileal wall. The catheter was connected to an S/5 
Tonometry Module (GE Healthcare Information Technologies AB) and used to 
measure mucosal partial pressure of carbon dioxide every 10 minutes. The mucosal-
arterial PCO2-gap (PCO2muc-art) was calculated as the difference between ileal mucosal 
PCO2 and arterial PCO2. 
MITOCHONDRIAL ENZYMES 
In paper IV, tissue samples from the ileal wall were homogenized in a KCl-based 
buffer using a Potter-Elvhjem homogenizer. Activity of citrate synthase, mitochondrial 
complex I and complex IV was analysed as described in detail elsewhere129. 
INTERVENTIONS 
Ringer’s ethyl pyruvate solution  
The resuscitation fluid Ringer’s ethyl pyruvate solution (REPS) was used in paper I. EP 
was bought from Sigma-Aldrich Sweden AB (Stockholm, Sweden), and used to 
prepare REPS (NaCl 130 mmol·L-1, KCl 4 mmol·L-1, CaCl 2.7 mmol·L-1, and EP 28 
mmol·L-1) with help from the hospital pharmacy. After 60 minutes of endotoxaemia, a 
bolus dose of 40 mg·kg-1 EP (corresponding to 12.3 ml·kg-1 of REPS) was given over 
10 minutes. After the bolus dose was administered, a continuous infusion of EP 40 
mg·kg-1·h-1 (12.3 ml·kg-1·h-1 of REPS) was started and continued throughout the 
experiment.  
Tezosentan 
The dual ET receptor antagonist tezosentan was used in papers II and III. Tezosentan is 
approximately 30-fold more potent on ETA receptors than on ETB receptors130. It is a 
very specific, competitive antagonist without agonistic effects. Tezosentan also has 
been found to have weak inhibitory effects on H1 central, 5-HT2A, and vasopressin V1 
receptors130, but these effects are likely to be of little importance compared to the potent 
effects on the ET receptors. Tezosentan is relatively short acting, and designed for 
intravenous use. There are no known active metabolites. In humans, the distribution 
half-life of tezosentan is 0.1 hours and the elimination half-life 3 hours131.  
In papers II and III tezosentan was intravenously administered after 120 minutes of 
endotoxaemia. A bolus dose of 1 mg·kg-1 was given over 10 minutes and followed by a 
continuous infusion of 1 mg·kg-1·h-1 throughout the experiment.  
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TBC3711 
The selective ETA receptor antagonist TBC3711 was used in paper III. TBC3711 has 
an affinity ratio between the ETA receptor and the ETB receptor of 441000:1132. The 
elimination half-life for TBC3711 is 6.6 hours in humans132. In paper III, TBC3711 
was administered intravenously as a bolus dose of 2 mg·kg-1 given over 15 minutes. 
Norepinephrine 
Norepinephrine is an agonist of α1, β1 and β2 adrenergic receptors, and a first-line 
vasopressor in the treatment of septic shock hypotension according to the SSC 
guidelines66. In paper IV, norepinephrine was infused intravenously after 24 hours of 
endotoxaemia to restore mean arterial pressure to baseline levels. The mean intravenous 
dose of norepinephrine was 318 ± 45 ng·kg-1·min-1. 
STATISTICS 
Paper I  
Changes in parameters over time were analysed according to a two-way repeated 
measures analysis of variance (ANOVA), the repeating variable being time. In case of a 
significant main effect, differences between groups at each time point were analysed 
using Bonferroni-corrected pairwise comparisons. 
Paper II 
Main effects were analysed using a two-way ANOVA with time as a repeating variable 
before intervention (T0-T120) and after intervention (T120-T300). The effects of 
tezosentan were determined by analysis of the time–treatment interaction between 
T120 and T300.  
Paper III 
Main effects were analysed using a two-way ANOVA with time as a repeating variable 
before intervention (T0-T120) and after intervention (T120-T300). If the overall F-ratio 
Figure 5. The molecular 
formula of tezosentan.  
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was significant, pairwise planned comparisons of the changes over time were 
performed. P-values were adjusted according to Bonferroni. 
Paper IV 
In the endotoxin group, changes over time between T0 and T24 were analysed with 
one-way ANOVA, Student’s paired t-test or Wilcoxon matched pair test, and 
interpreted as effects of endotoxemia. Effects of norepinephrine were evaluated with 
Student’s paired t-test or, in case of non-normal distribution, Wilcoxon matched pair 
tests using time-points T24 and T25.
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RESULTS 
PAPER I 
Systemic and pulmonary effects 
Endotoxaemia induced a hypodynamic response with decreasing CI and increasing 
systemic vascular resistance index (SVRI) and mean pulmonary artery pressure 
(MPAP), whilst MAP was maintained at baseline levels. CI was significantly lower in 
the REPS group at T60 before treatment. Mixed venous oxygen saturation (SvO2), 
systemic oxygen delivery index (DO2I), and systemic oxygen consumption index 
(VO2I) remained unchanged for the first 60 minutes of endotoxaemia. Arterial pH 
levels decreased, but base excess (BE), arterial lactate levels and anion gap remained 
unchanged. Haematocrit increased as a sign of haemoconcentration. 
Resuscitation with either REPS or RA after 60 minutes of endotoxaemia induced a 
temporary increase in CI, but then progressive deterioration ensued again. SVRI 
temporarily decreased after the initial fluid bolus, but increased again to reach levels 
above baseline at T300. MPAP remained elevated, but MAP deteriorated throughout 
the experiment. SvO2 and DO2I decreased, but VO2I increased over time. There were 
no significant differences between the REPS and the RA group in the effect on central 
haemodynamic and pulmonary parameters. Arterial pH decreased throughout the 
experiment due to a combination of metabolic and respiratory acidosis. BE decreased, 
and was significantly lower in the REPS group compared to the RA group at later time 
points. A significantly higher plasma chloride concentration in the REPS group 
explained the lower BE to some extent, but there was also a lower anion gap in the 
REPS group, indicating an additional source of the metabolic acidosis. Haematocrit 
remained elevated without any intergroup differences. 
Splanchnic perfusion 
Endotoxaemia appeared to decrease portal vein flow indexed to body weight (PVFI) 
and microcirculatory perfusion in the ileal mucosa and muscularis during the first 60 
minutes, but this was only statistically significant for the ileal mucosa. Hepatic 
microcirculation was initially unchanged by endotoxaemia. No intergroup differences 
were found for the above-mentioned parameters before treatment at T60, but renal 
artery flow indexed to bodyweight was lower in the REPS group at T60, presumably as 
a reflection of the difference seen in CI. There were no differences in renal 
microcirculation or diuresis before the start of treatment.  
Treatment with REPS or RA after 60 minutes of endotoxaemia did not induce any 
differences between the groups in regional blood flow, microcirculatory perfusion or 
urine output. PVFI and renal artery flow index decreased compared to baseline levels, 
although this did not reach significant levels for renal artery flow index. Microvascular 
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perfusion decreased over time at all sites, without intergroup differences. In the ileum, 
microvascular perfusion seemed to be preserved in the mucosa compared to the 
muscularis, indicating a functional autoregulation of mucosal microvascular perfusion.  
PAPERS II-III 
Systemic and pulmonary effects 
Effects of endotoxaemia 
Endotoxin administration resulted in a hypodynamic response in papers II-III. The 
decrease in CI was due to a reduction of stroke volume index, since heart rate 
concomitantly increased. In paper II MAP decreased compared to baseline levels, but 
in paper III MAP was maintained. SvO2 and DO2I decreased over time (paper II), but 
VO2I increased in response to endotoxin (paper II). Pulmonary capillary wedge 
pressure (PCWP) increased over time (paper II).  
Endotoxaemia induced pulmonary hypertension, and PO2 and PCO2 deteriorated in 
parallel (papers II-III). Metabolic and respiratory acidosis developed over time (papers 
II-III), with increased arterial lactate levels and a decrease in BE (papers II-III). 
Haemoglobin levels increased (papers II-III) indicating haemoconcentration. Arterial 
levels of ET-1-like immunoreactivity increased in response to endotoxin (papers II-III).   
Effects of ET receptor antagonism 
Tezosentan improved CI and stroke volume index compared to controls (papers II-III) 
and TBC3711 (paper III), but no differences in heart rate were found. Tezosentan also 
preserved SvO2 compared to controls (papers II-III), but compared to TBC3711 this 
effect did not reach statistical significance (p=0.07; paper III). The deterioration in 
DO2I seen in the control group was prevented by tezosentan (paper II), but there was no 
significant difference in VO2I (paper II).  
The effect of tezosentan on MAP compared to controls differed between papers II and 
III. In paper II there was no difference, but in paper III both tezosentan and TBC3711 
lowered MAP compared to controls. In the control group, PCWP increased compared 
to the tezosentan group (paper II). The pulmonary hypertension seen in controls was 
ameliorated by tezosentan (papers II-III) and TCBC3711 (paper III), resulting in an 
improvement of PO2 and PCO2 in treatment groups.  
Tezosentan improved pH compared to controls (papers II-III), but only in paper II did 
tezosentan significantly improve BE and arterial lactate. No differences in BE or 
arterial lactate levels could be found between TBC3711 and controls, but TBC3711 
improved pH due to a decrease in PCO2 (paper III). In paper II, tezosentan did not 
affect haemoglobin levels, but in paper III both tezosentan and TBC3711 decreased 
haemoglobin levels compared to controls. As expected when blocking the ETB 
                    Results 
  29 
receptor, tezosentan increased arterial levels of ET-1-like immunoreactivity compared 
to TBC3711 and controls.   
Splanchnic perfusion 
Effects of endotoxaemia 
Total splanchnic blood flow measured as PVFI (papers II-III) and splanchnic oxygen 
delivery index (paper II) were reduced in response to endotoxin administration. An 
initial increase in the superior mesenteric artery flow index (SMAFI) was followed by a 
progressive decline in flow. Microcirculatory perfusion in the ileal mucosa (papers II-
II), ileal muscularis (paper III), colonic mucosa (paper II) and liver (papers II-III) all 
decreased over time in a similar pattern. In parallel with this, the mucosal-arterial 
PCO2-gap (papers II-III) and mesenteric vein lactate levels (paper III) increased. 
Endotoxaemia also raised mesenteric vein levels of ET-1-like immunoreactivity (paper 
III). 
Effects of ET receptor antagonism 
PVFI was significantly improved with tezosentan compared to controls (papers II-III) 
and TBC3711 (paper III); this also resulted in an improved splanchnic oxygen delivery 
index (paper II). However, no differences in SMAFI were found between the groups 
(paper III).  
Microcirculatory perfusion in the ileal mucosa (papers II-III) and colon mucosa (paper 
II) were significantly improved with tezosentan compared to controls (papers II-III) and 
TBC3711 (paper III). In parallel with this, the increase in PCO2muc-art seen in controls 
(papers II-III) and the TBC3711 group (paper III) was attenuated. In the muscular layer 
of the ileum, the microcirculatory perfusion did not differ between groups (paper III). 
TBC3711 failed to improve ileal microcirculation or PCO2muc-art compared to controls.  
Tezosentan also had beneficial effects on mesenteric vein lactate levels compared to 
controls (paper III), but compared to TBC3711 this effect failed to reach statistical 
significance (p=0.05; paper III).  
The hepatic microcirculation did not significantly improve after administration of 
tezosentan (papers II-III) or TBC3711 (paper III). Also, no significant difference in 
hepatic microcirculatory perfusion could be found when comparing all of the animals 
(n=14) from the two controls groups and tezosentan groups in papers II and III (p=0.43; 
Figure 6). 
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PAPER IV 
Effects of endotoxaemia 
In paper IV, a state of hyperdynamic shock with an increased CI and systemic 
hypotension had developed after 24 hours of endotoxaemia. Although SvO2 increased, 
metabolic acidosis with a decrease in base excess and increased arterial lactate levels 
ensued. PCWP increased and urine output was preserved, indicating that fluid 
resuscitation was adequate. SaO2 and PCO2 did not significantly change during the first 
24 hours.  
SMAFI increased, but in spite of this ileal microcirculation deteriorated. Microvascular 
perfusion measured with LD decreased to a similar extent in the mucosa and in the 
muscular layer. The SDF derived parameters showed a similar pattern, with a decrease 
in MFI and percentage of perfused villi and an increase in heterogeneity index. In 
parallel with these microcirculatory changes, PCO2muc-art increased. 
Endotoxaemia significantly decreased citrate synthase (CS) and complex I activity, but 
complex IV activity remained unchanged. To correct for mitochondrial density, the 
ratio of complex I and complex IV to CS were calculated (complex I/CS and complex 
IV/CS respectively). No significant differences were found for complex I/CS (p=0.09) 
or complex IV/CS (p=0.21). 
Effects of increasing perfusion pressure with norepinephrine 
After 24 hours of endotoxaemia, a norepinephrine infusion was used to restore mean 
arterial pressure to baseline levels. CI and SvO2 increased further, but SMAFI remained 
unchanged. Norepinephrine did not induce any significant differences in PCWP, acid-
base parameters, pulmonary gas exchange parameters or urine output.  
Neither the intestinal microcirculation nor PCO2muc-art was significantly affected by 
norepinephrine treatment. On the mitochondrial level, norepinephrine increased 
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Figure 6. Hepatic microcirculatory 
perfusion values in control animals 
and tezosentan animals from paper 
II and III. N=14 in both groups. 
P=0.43 for time–treatment 
interaction between T120 and T300 
using two-way ANOVA. 
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complex I activity and complex I/CS in 5 out of 6 animals, but this did not reach 
statistical significance (p=0.12 and 0.18, respectively). No statistical differences were 
found in the activity of CS, complex IV or complex IV/CS. 
Sham animals 
In paper IV, 5 sham animals were used to rule out any non-endotoxaemic effects over 
time. Due to technical difficulties, SDF measurements and ileal wall biopsies were only 
obtained from three animals in the sham group. Sham animals did not exhibit any major 
changes in central haemodynamics, SMAFI, acid-base parameters, urine output, arterial 
lactate or body temperature over time. Microcirculatory parameters and PCO2muc-art also 
remained stable over time. In sham animals, CS was reduced to a similar extent as in 
the endotoxin animals after 24 hours, possibly due to the preoperative fasting period or 
to the fact that the animals were unable to ruminate. 
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DISCUSSION 
THE ENDOTOXIN MODEL 
The experiments in this thesis were performed using endotoxin infusion in two animal 
models: a shorter (5 hours) porcine model (papers I-III) and a longer (25 hours) sheep 
model (paper IV). Although many different models of sepsis have been used, there is 
no single ideal preclinical model, but rather a large number of complementary models 
with different strengths and weaknesses133. Endotoxin is considered to be an important 
part of the pathophysiology of gram-negative sepsis, and the administration of small 
doses of endotoxin to human volunteers induces haemodynamic, metabolic and 
haematologic changes that are qualitatively similar to those seen in septic patients68. 
Endotoxin is easy to use, dosing can be controlled, and the response is reproducible. 
However, results from animal models of endotoxaemia are not directly applicable to the 
complex clinical situation of bacterial sepsis in humans, and this should be kept in mind 
when interpreting the results. 
In shorter models of acute porcine endotoxaemia, the haemodynamic response is 
normally hypodynamic, with a decrease in CI and increase in systemic vascular 
resistance. This was also the case in the porcine experiments (papers I-III), where a 
hypodynamic cardiovascular response was elicited by endotoxin administration. The 
hypodynamic situation is different from the hyperdynamic response usually seen in 
septic shock patients, and this limitation of the model has led to concerns about the 
clinical relevance. Another limitation of the endotoxin model is that the cytokine 
response is more rapid and quantitatively larger than in models of cecal ligation and 
puncture, representing a focus of infection model134. However, several authors have 
concluded that endotoxin infusion can be a reasonable model of human sepsis, provided 
that the model chosen adequately replicates those features of the clinical syndrome that 
are the focus of the experiment68,69. With this in mind, studies using shorter models of 
endotoxaemia with a predominantly hypodynamic response56,135 can replicate many of 
the microcirculatory changes seen in septic patients, supporting the relevance of these 
models in this context. Still, since shorter, hypodynamic endotoxin models do not fully 
mimic the complexity of the human septic syndrome, findings should primarily be 
interpreted from a mechanistic point of view, and results cannot be extrapolated into the 
clinical and therapeutic setting.     
In porcine models of endotoxaemia, aggressive fluid resuscitation using up to 
70 ml·kg-1·h-1 has been used136 to avoid a hypodynamic response and normalize or 
increase CI. However, resuscitation with large amounts of fluid can also induce 
pulmonary oedema, and the management of fluid therapy in pigs137 is a delicate 
balance. Fluid resuscitation with 20 ml·kg-1·h-1 of saline with glucose 25 mg·ml-1 
elicited a hypodynamic response in paper II. In paper III, the total amount of fluid given 
was kept constant at 20 ml·kg-1·h-1, but to achieve better intravascular resuscitation 
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saline with glucose was to a large extent replaced by Ringer’s acetate (15 ml·kg-1·h-1). 
As a result, animals in the control group maintained MAP at baseline levels, but CI still 
decreased. Possibly, a more aggressive fluid resuscitation could have induced a 
hyperdynamic response to endotoxaemia, but in our pilot experiments using larger 
amount of fluids several of the animals developed pulmonary oedema.   
In paper IV, we aimed to create a model of endotoxaemic shock that would as far as 
possible mimic the clinical situation of hyperdynamic septic shock in patients. Sheep 
models using low-dose endotoxin infusion are known to replicate the human 
cardiopulmonary changes seen in septic shock, with increased CI and systemic 
hypotension71. Furthermore, the clinical course of sepsis in patients is often prolonged 
with multiple organ failure developing over days. In paper IV, the study period was 
extended to 25 hours, thereby allowing for a slowly progressing development of septic 
organ failure more clinically relevant than the shorter model of acute endotoxaemic 
shock.  
The sheep is also a very calm animal, and establishing a sheep model has the advantage 
that studies can also be performed in unanaesthetized animals, thereby avoiding any 
cardiovascular or inflammatory effects of the anaesthetics used. However, the use of 
SDF monitoring in paper IV necessitated the use of an anesthetized model in order to 
avoid suffering of the animals and to obtain steady pictures. 
The animals used in this thesis were subjected to extensive surgical preparation, and the 
results should be interpreted in this context. However, in order to achieve a 
comprehensive monitoring of systemic haemodynamics and splanchnic perfusion, the 
use of invasive monitoring equipment is necessary considering the currently available 
techniques. 
MONITORING OF MICROCIRCULATORY PERFUSION 
Laser Doppler flowmetry 
LD is an established method of measuring microcirculatory perfusion in the intestinal 
mucosa, and over the years it has been used in numerous studies in humans138 as well 
as in experimental animal models139. Previous studies have shown that LD values 
correlate strongly to whole organ blood flow in the intestine140 as well as in the liver141 
in normal conditions. Moreover, microcirculatory perfusion measured in the intestinal 
mucosa with LD correlate strongly to simultaneous mucosal blood flow measurements 
using the microsphere technique or hydrogen gas clearance142. 
Laser Doppler flowmetry allows for the real-time, continuous, quantitative 
measurement of microvascular perfusion, but the inability to determine measurement 
depth and volume remains a limitation of the technique. Using Monte Carlo simulations 
of light propagation in tissue, Fredriksson et al. recently estimated the measuring depth 
of probes similar to the ones used in this thesis to be 0.4 mm in the liver, 0.55 mm in 
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skeletal muscle, and 0.53 mm in skin126. Considering the optical properties of the 
intestinal wall, it is reasonable to assume that the intestinal measuring depth is also in 
this range. Ileal villi height in pigs similar in size to those used in this thesis is 0.5-0.6 
mm143,144 and crypth depth approximately 0.45 mm143, and available data indicate 
similar conditions in the ileal mucosa of sheep145. This indicates that the laser Doppler 
signal from the mucosal probes was mainly derived from the villous part of the mucosa.  
A prominent feature of the microcirculatory changes seen in sepsis and endotoxaemia 
is spatial hetereogeneity within the tissue. A limitation of laser Doppler flowmetry in 
this setting is that it measures perfusion in the entire measurement volume, and hence it 
cannot be used to evaluate changes of microcirculatory perfusion heterogeneity. The 
fact that values are arbitrary and should be regarded as the product of red blood cell 
velocity and tissue haematocrit, rather than linear blood flow per se, can complicate 
comparisons with whole organ blood flow. The measurement depth and volume of 
laser Doppler flowmetry are affected by instrumental factors as well as tissue factors. If 
tissue properties change over time, the absorption or scattering of light in the tissue can 
be altered, possibly affecting measurement volume and laser Doppler perfusion 
values126.  
Measurements are sensitive to probe migration, pressure from the probe itself, and 
motion artefacts125. In the experiments performed in this thesis, motion artefacts did not 
occur, presumably due to the combined effects of anaesthetics and endotoxaemia. 
Probe migration was avoided by attaching the probe to a small holder gently sutured to 
the surface of the organ with great care being taken to avoid pressure artefacts.  
Sidestream dark field imaging 
SDF is a recently developed videomicroscopy technique that has been used to directly 
visualize the microcirculation of the intestinal mucosa in patients as well as in 
experimental animal models. The device is small and handheld, and no contrast dye is 
needed to visualize the microcirculation. The optical field of view when using a 5× 
objective is approximately 0.94 mm × 0.75 mm, and the on-screen magnification is 
×380127.  
SDF makes it possible to directly evaluate changes in the microvascular network, 
including capillary density and heterogeneity of perfusion. The technique is sensitive to 
pressure and motion artefacts, and contrast and focus must be adjusted to obtain images 
of adequate quality. The vascular wall cannot be visualized with SDF, meaning that 
only vessels containing red blood cells can be detected146. The technique does not allow 
for continuous evaluation of the microcirculation for extended periods of time. 
Software for computer-assisted analysis of microvascular parameters can be used when 
evaluating the videos, but manual intervention is still needed for vessel identification 
and blood flow measurements.  
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The SDF-derived variables used to evaluate the microcirculation in paper IV were in 
line with previously published guidelines127. The microvascular flow index was used to 
semiquantitatively evaluate the main type of capillary blood flow in each quadrant. 
Using this variable, four categories of flow are identified using a scale ranging from 0 
to 3; 0 represents no flow, 1 represents intermittent flow, 2 represents sluggish flow, 
and 3 represents normal flow. The MFI score is relatively easy to measure, but the 
score is ordinal, and this complicates interpretation of the results. Moreover, the scale 
used does not take into consideration flow velocities in the supranormal range. Based 
on the MFI values, the heterogeneity index was calculated, as previously described. 
The percentage of perfused villi was calculated as a surrogate parameter for functional 
capillary density. The fact that the SDF-derived variables used are semiquantitative is a 
limitation of the analysis. However, the possibility to visualize individual vessels and 
determine heterogeneity of flow is an advantage, compared to laser Doppler flowmetry. 
When used in paper IV, the SDF device mainly visualized vessels in the ileal villi, and 
hence, the SDF-derived parameters should be regarded as representing the 
microcirculation in the villous part of the mucosa. 
Tonometry  
In papers II-IV, an air tonometry catheter was placed in the lumen of the ileum and 
used to measure gut mucosal PCO2. The air in a semi-permeable silicon balloon is 
allowed to equilibrate with the mucosal PCO2 for 10 minutes, after which the air is 
automatically aspirated and the PCO2 level is analysed. Monitoring of gut mucosal 
PCO2 with tonometry is based on the principle that tissue PCO2 levels increase in 
conditions with inadequate tissue perfusion147. The tissue level of PCO2 is influenced 
by the arterial PCO2, and the mucosal-arterial PCO2-gap is usually calculated. When 
arterial CO2 content is stable, the two main factors influencing PCO2 in the mucosa are 
perfusion and the metabolic production of PCO2147, but an impaired perfusion seems to 
be the main determinant of tissue CO2 accumulation148. Several studies have shown a 
close relationship between PCO2 levels and mucosal microcirculation101,149,150. Still, the 
PCO2-gap should not be interpreted as a direct measure of microcirculatory blood flow, 
but rather as a reflection of the adequacy of microvascular perfusion in relation to 
oxygen demand.  
The linearity between mucosal CO2 content and PCO2 is dependent on stable 
conditions, and stability is hard to achieve when studying the progression of 
endotoxaemia and shock. Blood oxygen saturation affects the relationship between 
blood CO2 content and PCO2, a phenomenon called the Haldane effect. This means that 
alterations of arterial oxygen saturation or tissue oxygen extraction can affect the 
mucosal-arterial PCO2-gap independent of changes in mucosal CO2 content, and this is 
a potential source of error151.  
A. Andersson 
36 
EFFECTS OF ETHYL PYRUVATE 
The anti-inflammatory and reactive oxygen species scavenging properties of EP was 
documented in several pre-clinical animal models77. Theoretically, EP could also have 
positive inotropic effects through metabolic support resulting from the administration 
of pyruvate. Early studies suggested direct positive cardiac effects of EP78, and EP also 
improved intestinal microcirculation in a mouse model of mesenteric 
ischaemia/reperfusion79. Since the data on the effects of EP in sepsis and endotoxaemia 
were mainly derived from small animal models at the time, we wanted to evaluate the 
effects of resuscitation with REPS on haemodynamics and metabolic parameters in a 
large animal model of acute endotoxaemia (paper I). 
Resuscitation with a bolus dose of either REPS or RA after 60 minutes of 
endotoxaemia temporarily improved CI compared to baseline values, but this was soon 
followed by a progressive deterioration of CI, and at the end of the experiment all 
animals were again severely hypodynamic. The change in systemic haemodynamic 
parameters from intervention to the end of the experiment did not differ between the 
REPS group and the RA group, indicating that EP did not have direct positive inotropic 
effects in this model. Microcirculatory perfusion in the liver, kidney, and ileal mucosa 
and muscularis deteriorated throughout the experiment without any intergroup 
differences.   
In contrast to this, EP improved central haemodynamics in a 24-hour model of porcine 
endotoxaemic shock152, and significantly prolonged the time to arterial hypotension in a 
30-hour model of ovine peritonitis153. The results from paper I indicate that positive 
cardiovascular effects seen in studies of longer duration could have been secondary to 
the anti-inflammatory effects of EP rather than due to direct positive cardiac effects. 
However, it is possible that hypovolaemia developing during later time points in paper I 
could have concealed a positive inotropic effect of EP in our model. 
One explanation for the lack of effect seen with EP is the relatively short timeframe of 
the study. EP is a potent inhibitor of the late-acting proinflammatory cytokine HMGB-
177, previously shown to be a mediator of LPS-induced lethality. Positive central 
haemodynamic and microcirculatory effects of inhibiting HMGB-1 are unlikely to 
appear in the 5-hour study period used in paper I. 
Animals in the REPS group showed significantly lower BE and a higher anion gap at 
later time points. This could in part be explained by the higher chloride content in 
REPS compared to RA, but the higher anion gap suggests that the lower BE was not 
explained only by differences in chloride content. Pyruvic acid is a strong acid (pKa≈3), 
and this is a possible explanation for the difference in anion gap. Also, even though no 
differences in perfusion parameters were found, a release of tissue acids secondary to 
inadequate perfusion in the REPS group cannot be ruled out.   
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There are several limitations to paper I. The relatively short model and the difference in 
chloride content between REPS and RA have been addressed above. Also, the study 
did not evaluate possible positive effects of EP on inflammatory cytokines or tissue 
damage. Considering CI and renal blood flow, the REPS group had significantly lower 
values compared to the RA group before treatment, after 60 minutes of endotoxaemia. 
In this model, the initial peak in pulmonary hypertension occurred between 50 and 70 
minutes after the start of endotoxaemia, but in two pigs in the RA group the initial 
increase in MPAP started to revert before intervention after 60 minutes. The difference 
in CI and renal blood flow seen after 60 minutes of endotoxaemia was most likely due 
to this individual variability in the time point for reversal of the initial peak in MPAP. 
This is also supported by the fact that the degree of change of systemic haemodynamic 
variables from 60 to 300 minutes was identical between the groups. Still, the fact that a 
significant intergroup difference in a central parameter was found before treatment 
makes data interpretation more complicated.  
Interestingly, although EP has been proven beneficial in several preclinical animal 
models of endotoxaemia or sepsis, there have also been reports of negative effects of 
EP administration. In a mouse model of endotoxaemia testing several different doses of 
EP, EP administration decreased early (3 hours) NF-κB and cytokine levels, but at a 
later (9 hours) time point the levels were increased compared to controls154. When all 
groups receiving EP were combined, EP also significantly increased the hazard ratio of 
death154. Activation of NF-κB pathway is an important part of the dysregulated 
inflammatory response that is characteristic of sepsis. However, the effects of NF-κB 
are complex, including pro-inflammatory, anti-inflammatory and anti-apoptotic 
properties, and concerns have been raised that a therapeutic strategy based on the 
inhibition of NF-κB could, in some cases, have unintended negative effects155,156. 
A phase II trial of the effects of EP in high-risk patients undergoing cardiopulmonary 
bypass was recently performed. The trial was terminated by the sponsor after 102 
patients due to problems with the drug container closure system. Data from the trial 
showed that the administration of EP did not appear to confer any benefit to high-risk 
cardiac surgical patients undergoing cardiopulmonary bypass157. So far, no data on the 
effects of EP on patients with sepsis have been presented.  
EFFECTS OF ENDOTHELIN RECEPTOR ANTAGONISTS 
ET-1 has been implicated as one of the possible mediators of the gut microcirculatory 
failure in sepsis. Tissue levels of ET-1 are increased in the intestinal mucosa in 
endotoxaemia102, and antagonizing ET-1 has proven beneficial to the intestinal 
microcirculation in rat models of bacteraemia39 and endotoxaemia102.  
Mixed endothelin receptor antagonism with tezosentan was effective in improving 
microcirculatory perfusion in the ileal (papers II-III) and colonic (paper II) mucosa. 
Although this improvement probably to some extent was due to improved systemic 
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haemodynamics, we did not find any statistically significant differences in SMAFI in 
paper III, indicating that tezosentan also had direct positive effects on the 
microcirculation in the ileal mucosa.  
In a porcine model of peritonitis, Krejci et al found that the mixed ET receptor 
antagonist bosentan improved microvascular perfusion in the jejunal mucosa compared 
to baseline, but could not demonstrate a statistically significant improvement compared 
to controls101. Of the ET receptors, the ETA receptor has been suggested to be the most 
important receptor mediating vasoconstriction, while the ETB receptor also mediates 
vasodilation and clearance of circulating ET-1. Tezosentan has more pronounced 
effects on ETA than on ETB receptors compared to bosentan, 30:1 compared to 20:1, 
possibly rendering tezosentan more beneficial to the intestinal microcirculation. 
Differences in experimental models, fluid loading and drug dosing could also explain 
the better effect seen with tezosentan in this model. 
Tezosentan also improved PCO2muc-art (papers II-III), indicating a better balance 
between oxygen supply and demand in the intestinal mucosa. This is in line with 
previous studies using bosentan in similar models of porcine endotoxaemia100,105.  
The improvement of mucosal microcirculation did not occur at the expense of 
perfusion in the muscular layer, since perfusion in the muscular layer did not differ 
between controls and the tezosentan group (paper III). The fact that tezosentan did not 
affect perfusion in the muscular layer is in accordance with the results of Krejci et al101. 
In endotoxaemia and sepsis, mucosal microcirculatory perfusion is initially better 
preserved than muscular perfusion through a redistribution of microvascular flow158. 
Our findings indicate that ET-1 is not of major importance to this redistribution of flow 
in the intestinal wall. 
The physiological response to endothelin receptor activation is hard to predict and 
varies depending on the receptor population in different tissues. Theoretically, selective 
ETA receptor antagonism has advantages in preserving ETB receptor-mediated 
vasodilation and clearance of ET-1, and in a previous study selective ETA receptor 
antagonism improved microcirculation in the ileal submucosa in a rat model of 
endotoxaemia102. However, selective ETA receptor antagonism with TBC3711 failed to 
improve microcirculation in the ileum and mucosal PCO2 levels, indicating that also the 
ETB receptor can mediate intestinal microcirculatory dysfunction in this model of 
endotoxaemia. Still, the interaction between the endothelin receptors is very complex, 
and it has been proposed that a cross-talk exists between the ETA and the ETB 
receptors, making interpretation of the role of the different ET receptor subtypes 
complicated. Ozaki et al showed that activation of the ETA receptor induced changes in 
the ETB receptor through ETA receptor-mediated intracellular signalling, thereby 
altering the affinity of the ETB receptor to ligands89. In line with this, Just et al found 
that the effects of the ETB receptor on renal blood flow differed depending on the 
degree of ETA receptor activation159. When both receptors were stimulated 
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simultaneously, the ETB receptor induced vasodilation, but when the ETB receptor was 
selectively activated without concomitant ETA receptor stimulation the response 
seemed to be predominantly vasoconstriction. The existence of a cross-talk between the 
ET receptors was not investigated in this thesis, but the results show that mixed ET 
receptor antagonism is necessary to improve microcirculation in the ileal mucosa in 
porcine endotoxaemia.   
Previous findings from rat models have indicated that ET-1 is an important mediator of 
hepatic microcirculatory dysfunction in endotoxaemia108,160, but mixed endothelin 
receptor antagonism failed to improve hepatic microcirculation in porcine peritonitis101 
and in a model of systemic inflammation in rats115. Although tezosentan improved 
portal vein flow, no statistically significant improvement in hepatic microcirculatory 
perfusion could be demonstrated in paper II or III. TBC3711 failed to improve either 
portal vein flow or hepatic microcirculation compared to controls (paper III).  
The increase seen in portal vein flow with tezosentan indicated an increased blood flow 
to the liver, but since we did not measure hepatic artery flow, total hepatic blood flow 
could not be calculated. However, the hepatic arterial buffer system is impaired in 
endotoxaemia63, and hence it is not likely that the lower portal vein flow in controls 
was fully compensated for by a higher hepatic artery flow. There are several possible 
explanations for the lack of improvement of hepatic microcirculatory perfusion in spite 
of the apparent higher hepatic blood flow in the tezosentan group. Microcirculatory 
perfusion was measured at the surface of the liver, and possibly perfusion could have 
been redistributed to deeper layers in the tezosentan group. Moreover, it has been 
suggested that laser Doppler flowmetry readings are more sensitive to changes in 
hepatic artery flow than portal vein flow161, and if true, this could, to some extent, 
explain our results. The use of the laser Doppler technique did not allow us to evaluate 
changes in microcirculatory heterogeneity, and ET receptor antagonism could have 
improved heterogeneity within the microcirculation without affecting the measure of 
perfusion obtained with LD. The relatively small number of animals studied must also 
be taken into account, and possibly differences could have been found if the number of 
animals were increased. However, when combining controls and tezosentan-treated 
animals from papers II and II, thereby increasing the number of animals in each group 
to 14, there was still no significant difference in hepatic microcirculatory perfusion 
(p=0.43) to be found, further supporting the conclusion that ET-1 is not a main 
determinant of hepatic microcirculatory perfusion in porcine endotoxaemia.  
EFFECTS OF CHANGES IN REGIONAL BLOOD FLOW AND PERFUSION 
PRESSURE 
Current protocols for the treatment of septic shock are to a large extent based on 
achieving predetermined goals for central haemodynamic parameters66. However, 
microcirculatory alterations can persist even though haemodynamic goals of treatment 
protocols are met, and in septic patients with comparable systemic haemodynamics 
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persistent microcirculatory alterations have been correlated to patient outcome3,33. Data 
from recent studies indicate that microcirculatory changes seem to be rather dissociated 
from central haemodynamic parameters, but the microcirculation will obviously be 
severely affected below certain levels of flow and perfusion pressure. However, these 
levels so far remain to be defined.   
In paper IV, endotoxaemia induced intestinal microcirculatory disturbances measured 
with both laser Doppler flowmetry and SDF in spite of a substantial increase in 
SMAFI, strengthening the hypothesis that gut microcirculatory dysfunction can appear 
independent of changes in systemic and regional blood flow, and demonstrating that 
increasing whole organ blood flow is not necessarily an effective therapeutic approach 
for the microcirculation. The data from papers II and III further support the notion that 
the association between regional blood flow and intestinal microcirculatory changes is 
rather weak. Moreover, the increase seen in arterial-mucosal PCO2-gap indicates that 
an imbalance between oxygen supply and demand in the mucosa developed in parallel 
with the increase in SMAFI.  
In line with the findings in paper IV, two previous studies found severe 
microcirculatory derangements in the ileal mucosa in spite of a maintained superior 
mesenteric artery flow,
 
using a 12-hour porcine model of cholangitis162 and a short-term 
model of ovine endotoxaemia56, respectively. Furthermore, severe decreases in ileal 
percentage of perfused villi have been found in parallel with maintained163 and 
increased164 portal vein flow in 24-hour models of porcine endotoxaemic shock. Taken 
together, these results indicate that regional blood flow changes are not the main factor 
behind the microcirculatory failure seen in the ileal mucosa in sepsis and 
endotoxaemia.  
In paper IV, microcirculatory perfusion in the muscular layer and the mucosal layer 
was reduced to a similar extent by endotoxaemia, indicating that the increase in 
intestinal blood flow was not directed to either the mucosa or the muscularis of the 
ileum. A possible explanation for this discrepancy is that perfusion was directed 
towards the submucosa or the deeper layers of the mucosa or muscularis, layers 
presumably not penetrated by the laser Doppler probes, and not visualized using SDF. 
Also, changes in microvascular perfusion can be heterogeneous between different parts 
of the intestines36, and regional blood flow could have been directed to another part of 
the intestine. The reports of the existence of an arteriovenous anastomotic network in 
the submucosa165, possibly contributing to the shunting of flow, are not consistent, and 
the existence of any extensive anastomotic network in the submucosa remains 
questionable. 
Moreover, comparing changes in regional blood flow measured with ultrasonic flow 
probes and microvascular perfusion measured with laser Doppler probes is somewhat 
complicated, since the measures of perfusion provided differ between the two devices. 
While the ultrasonic flow probes provide a measure of linear flow, expressed as 
ml/min, the laser Doppler perfusion readings are influenced by both the velocity of red 
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blood cells and the tissue haematocrit. The decrease in systemic haematocrit seen after 
24 hours of endotoxaemia probably contributed to the discrepancy between changes in 
regional blood flow and microvascular perfusion in the mucosa and muscularis. The 
magnitude of the influence of the change in haematocrit is difficult to determine, since 
microvascular haematocrit differs from systemic haematocrit due to the Fåhreus 
effect166 and the plasma skimming phenomenon13. Haemodilution per se can also 
redistribute flow between different capillary networks within a tissue167. The possibility 
of variations in the volume of tissue monitored by laser Doppler flowmetry must also 
be considered. Changes in the optical properties of the tissue over time, for instance due 
to increased tissue oedema, could have influenced penetration depth and thereby 
measurement volume126.   
In paper IV, microcirculatory perfusion was reduced after 24 hours of endotoxaemia in 
parallel with a decrease in MAP from 90 mm Hg to 60 mm Hg, indicating that the 
reduction in perfusion pressure could be a factor contributing to microcirculatory 
dysfunction. In order to evaluate the effects of elevating perfusion pressure with 
norepinephrine, MAP was restored using a continuous norepinephrine infusion.  
The intestinal microcirculatory effects of norepinephrine have been investigated in 
various animal models, with different studies indicating beneficial119, detrimental67,120, 
or no effects121,122, but these studies have mainly been performed in short-term models 
of sepsis or endotoxaemia. However, adrenergic receptor function is altered over 
time168,169, necessitating the use of studies of longer duration in order to better mimic 
the situation in septic shock patients.  
Restoring MAP with norepinephrine did not significantly affect either lased Doppler-
derived perfusion or SDF-derived variables of intestinal microcirculatory blood flow.  
Neither did the mucosal-arterial PCO2-gap change significantly, indicating that 
norepinephrine treatment did not alter the balance between oxygen supply and demand 
in the ileal mucosa.  
Since restoring MAP with norepinephrine did not affect SMAFI, the microcirculatory 
effect of increasing perfusion pressure could be evaluated without changes in regional 
flow complicating the picture. The findings in paper IV indicate that elevating 
perfusion pressure is not an effective treatment for intestinal microcirculatory 
dysfunction in endotoxaemic shock, at least not after several hours of hypotension. This 
is in line with two recently published investigations where increasing perfusion 
pressure with norepinephrine failed to significantly improve sublingual 
microcirculation in septic shock patients170,171. However, we cannot rule out that the 
microcirculation could have improved if perfusion pressure was increased earlier in the 
course of endotoxaemia, but over time the microcirculation was rendered unresponsive 
to changes in perfusion pressure.  
In sepsis, both microcirculatory failure and mitochondrial dysfunction are thought to 
play a role in the progression to multiple organ failure and death29. After 24 hours of 
endotoxaemia, mucosal-arterial PCO2-gap was significantly increased in parallel with 
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microcirculatory dysfunction and a significant decrease in mitochondrial complex I 
enzyme activity. Microcirculatory perfusion disturbances have previously been 
indicated as an important factor contributing to increases in mucosal PCO2 levels in 
sepsis149,150, but the role of mitochondrial dysfunction in this context is still unclear. 
However, given the findings in paper IV, it is reasonable to assume that both 
microcirculatory and mitochondrial alterations contributed to the mucosal acidosis 
induced by endotoxaemia.  
Although no significant difference in mitochondrial enzyme activity was found after 
the initiation of norepinephrine treatment, complex I and complex I/CS activity 
increased in five out of six animals from which biopsies were obtained. Reguirea et al. 
have previously demonstrated that norepinephrine improved liver mitochondrial 
complex I activity in a porcine model of endotoxaemia172, a finding that supports the 
possibility of a beneficial effect of norepinephrine on intestinal mitochondrial function. 
Given the results presented here and those of Reguirea et al., further studies 
investigating the effects of norepinephrine on mitochondrial function in sepsis and 
endotoxaemia are warranted.     
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CONCLUSIONS 
 
 
• In endotoxaemic shock, gut microcirculatory disturbances develop in spite of an 
increase in superior mesenteric artery flow, demonstrating the loose connection 
between changes in regional blood flow and intestinal microcirculatory 
perfusion in endotoxaemia. 
  
• Elevating perfusion pressure does not seem to be an effective treatment for gut 
microcirculatory derangements in ovine endotoxaemic shock. 
 
• The finding that gut microcirculatory perfusion has a weak correlation to 
systemic and regional indices of flow and pressure in endotoxaemia strengthens 
the hypothesis that monitoring and therapies directed at the microcirculation 
could be of value in sepsis. 
 
• The endothelin system is an important mediator of microcirculatory dysfunction 
in the ileal mucosa in endotoxaemia, and mixed endothelin receptor antagonism 
is needed to counteract these endothelin-induced microcirculatory disturbances. 
 
• The endothelin system does not seem to be an important factor contributing to 
hepatic microcirculatory failure in endotoxaemia.  
 
• In porcine endotoxaemic shock, resuscitation with Ringer’s ethyl pyruvate 
solution does not have initial beneficial effects on haemodynamics, splanchnic 
perfusion, or acid-base status compared to Ringer’s acetate.  
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